Close Menu

Gene Silencing/Gene Editing

News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.

The diagnostic is composed of Agilent's Bravo automation workstation and Mammoth's DETECTR BOOST SARS-CoV-2 assay.

The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.

The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated. 

The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.

The funding will help the company further develop its INSPECTR molecular diagnostic platform into a test that can be used in various settings.